VYNE Therapeutics
VYNE
105 hedge funds and large institutions have $132M invested in VYNE Therapeutics in 2020 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 33 increasing their positions, 25 reducing their positions, and 20 closing their positions.
32% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 25
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.04% less ownership
Funds ownership: 0.7% → 0.66% (-0.04%)
1% less funds holding
Funds holding: 106 → 105 (-1)
5% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 20
17% less capital invested
Capital invested by funds: $160M → $132M (-$28M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.64M |
| 2 |
State Street
Boston,
Massachusetts
|
+$749K |
| 3 |
6CM
683 Capital Management
New York
|
+$679K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$594K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$442K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$2.95M |
| 2 |
Millennium Management
New York
|
-$2.16M |
| 3 |
CCM
CAAS Capital Management
New York
|
-$2.05M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$1.26M |
| 5 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
-$1.12M |
VYNE Hedge Fund Activity: Q3 2020 in Review
105 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q3 2020, worth a combined $132M — down 17% from $160M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of VYNE and 19 opened new positions — a net loss of 1 holder — while 25 trimmed existing stakes and 33 added.
The largest buyer was BlackRock, adding an estimated $2.64M. The largest seller was Vivo Capital, cutting an estimated $2.95M.
- 105 institutional investors held VYNE Therapeutics (VYNE) as of Q3 2020, down from 106 in Q2 2020.
- Funds reported $132M of VYNE Therapeutics stock for Q3 2020, down 17% quarter-over-quarter.
- 19 funds opened new VYNE Therapeutics positions in Q3 2020 and 20 closed out, a net change of -1 holder.
- The largest VYNE Therapeutics buyer in Q3 2020 was BlackRock, an estimated $2.64M added.
- The largest VYNE Therapeutics seller in Q3 2020 was Vivo Capital, an estimated $2.95M sold.
Based on aggregated 13F filings for Q3 2020.